Jooryung Huh
Overview
Explore the profile of Jooryung Huh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
228
Citations
3590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shin S, Ko J, Hwang H, Huh J, Lee C, Lee J, et al.
Pathology
. 2024 Jan;
56(3):374-381.
PMID: 38296676
Pellino-1 plays a role in regulating inflammation and immune responses, and its effects on tumours are complex, with different outcomes reported in various studies. Additionally, the role of Pellino-1 in...
2.
Sung H, Kim D, Yoon D, Cho H, Huh J, Suh C, et al.
Hum Pathol
. 2023 Jul;
139:106-116.
PMID: 37517597
Double expressor lymphoma (DEL) is a subset of diffuse large B-cell lymphoma (DLBCL) characterized by the co-expression of MYC and BCL2 proteins with a poor prognosis. However, there are no...
3.
Hwang H, Sung H, Kim M, Yoon D, Park C, Huh J, et al.
Leuk Lymphoma
. 2022 Sep;
63(13):3072-3081.
PMID: 36167334
The clinical significance of extra copy (EC) genotypes of , , and have not been fully elucidated. We evaluated the EC and translocation statuses of , , and in 190...
4.
Jeong H, Cho H, Hong J, Lee D, Kim S, Lee K, et al.
Front Oncol
. 2022 Jun;
12:888925.
PMID: 35712469
Among patients with diffuse large B-cell lymphoma (DLBCL) involving the same side of the diaphragm, the prognostic implications of extranodal disease or its contiguity with the nodal lesion remain unclear....
5.
Kang S, Cho H, Kim S, Lee K, Kang E, Park J, et al.
Cancer Res Treat
. 2022 Apr;
55(1):314-324.
PMID: 35381163
Purpose: Prognostic Index for Natural Killer Lymphoma (PINK) is the most widely accepted prognostic model for patients withextranodal natural killer/T-cell lymphoma (ENKTL) treated with non-anthracycline-based therapy. We aimed to evaluate...
6.
Albitar M, Zhang H, Goy A, Xu-Monette Z, Bhagat G, Visco C, et al.
Blood Cancer J
. 2022 Feb;
12(2):25.
PMID: 35105854
Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology; however, these biological subgroups overlap clinically. Using machine learning, we developed...
7.
Roh J, Cho H, Pak H, Lee Y, Lee S, Ryu J, et al.
Mod Pathol
. 2021 Nov;
35(4):480-488.
PMID: 34764434
Overexpression of the BCL2 protein has been reported as a poor prognostic factor for diffuse large B-cell lymphoma (DLBCL). However, there are currently no standardized criteria for evaluating BCL2 protein...
8.
Roh J, Yoon D, Lee Y, Pak H, Kim S, Han J, et al.
Am J Surg Pathol
. 2021 Nov;
46(3):289-299.
PMID: 34739417
Diffuse large B-cell lymphoma (DLBCL) is a fatal heterogenous neoplasm. Recent clinical trials have failed partly due to nebulous criteria for defining high-risk patients. Patients with double-expresser lymphoma (DEL) have...
9.
Kim H, Cho H, Sohn B, Park C, Huh J, Ryu J, et al.
Leuk Lymphoma
. 2021 Oct;
63(1):124-130.
PMID: 34702115
We aimed to investigate the prognostic value of serum β2-microglobulin in patients with peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). A cohort study of PTCL-NOS patients ( = 147) was conducted....
10.
Koh J, Jang I, Mun S, Lee C, Cha H, Oh Y, et al.
Blood Adv
. 2021 Sep;
5(20):3919-3930.
PMID: 34535012
Recent studies identified germline mutations in HAVCR2 (encoding T-cell immunoglobulin mucin 3) as a genetic factor that predisposes to subcutaneous panniculitis-like T-cell lymphoma (SPTCL). However, the differences between HAVCR2-mutated (HAVCR2MUT)...